Moderna (MRNA)
(Real Time Quote from BATS)
$123.03 USD
+1.14 (0.94%)
Updated May 9, 2024 04:00 PM ET
After-Market: $122.60 -0.43 (-0.35%) 4:18 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MRNA 123.03 +1.14(0.94%)
Will MRNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRNA
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Earnings Season Could Be Great for Moderna (MRNA)
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Other News for MRNA
10 Health Care Stocks With Whale Alerts In Today's Session
Novo Nordisk, Flagship to develop next-generation obesity drugs
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and ACELYRIN, INC. (SLRN)
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), ACELYRIN, INC. (SLRN) and Moderna (MRNA)
Moderna price target raised by $15 at Deutsche Bank, here's why